Molecular Devices Announces Next-Generation SpectraMax MiniMax 300 Imaging Cytometer
Molecular Devices, the market leader in microplate reader technology for more than 25 years, has announced the next-generation SpectraMax MiniMax 300 Imaging Cytometer.
This MiniMax 300 imaging cytometer enables both cellular visualisation and first-of-its-kind stain free cell-based analysis on the field-upgradable SpectraMax i3 Multi-Mode Microplate Reader. Brightfield and fluorescence-based green and red channel cellular image acquisition and analysis is made simple using the SoftMax Pro software workflow. Combining cellular imaging with stain-free cell counting and confluency measurements with microplate-based applications, scientists now have more ways to compress their workflows and increase efficiency.
The SpectraMax MiniMax 300 Imaging Cytometer now features the patent-pending StainFree Cell Detection algorithm, which enables cell confluency and cell counting measurements on an imaging plate reader without the need for destructive stains, saving researchers valuable time and money. With two additional fluorescence detection channels — green and red — researchers may now perform and analyse a wide range of cellular viability and cell toxicity assays, including ratiometric assays such as transfection efficiency.
The SpectraMax i3 system offers three integrated detection modes and its flexible design enables a wide array of assay possibilities. The patented user-exchangeable cartridge design expands the system's detection capabilities with cartridges such as the recently launched ScanLater Western Blot Detection System, which enables protein analysis on a plate reader.
The SpectraMax i3 platform with MiniMax 300 Imaging Cytometer and ScanLater Western Blot System are all managed through SoftMax Pro Data Acquisition and Analysis Software, recognised industry-wide for its ease of use. With simple to set-up plate reader prompts and pre-defined analysis features, results are realised and analysed quickly. The SpectraMax i3 System is also available for use in GMP and GLP labs when used with SoftMax Pro 6 GxP Microplate Data Compliance Software.
Kevin Chance, President of Molecular Devices commented: “The patent-pending StainFree Cell Detection algorithm available on the SpectraMax MiniMax 300 Imaging Cytometer showcases Molecular Devices’ extensive experience in both cellular imaging and image analysis. Adding this unique cellular imaging capability to the SpectraMax i3 microplate reader platform enables scientists to perform non-destructive cell counting and confluency measurements in the same microplate as downstream microplate based assays.”
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance